View Older Stories
-
Mirum Pharmaceuticals, Inc. (MIRM) Misses Q1 EPS by 1309c ; Offers Guidance
-
Baird Reiterates Outperform Rating on Mirum Pharmaceuticals (MIRM)
-
Mirum Pharmaceuticals (MIRM) PT Raised to $135 at Evercore ISI
-
Mirum reports volixibat meets primary endpoint in cholangitis study
-
Mirum Pharmaceuticals (MIRM) PT Raised to $130 at Stifel
-
Mirum Pharmaceuticals (MIRM) PT Raised to $112 at Baird
-
Mirum Pharmaceuticals (MIRM) PT Raised to $150 at H.C. Wainwright
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Mirum Pharmaceuticals (MIRM) Reiterated at Overweight by Cantor Fitzgerald
-
Mirum Pharmaceuticals (MIRM) PT Raised to $125 at TD Cowen
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
-
Citizens Reiterates Market Outperform Rating on Mirum Pharmaceuticals (MIRM)
-
Morgan Stanley Reiterates Overweight Rating on Mirum Pharmaceuticals (MIRM) amid study enrollment, screening completion
-
Mirum Pharmaceuticals (MIRM) PT Raised to $126 at Evercore ISI
-
Mirum Pharmaceuticals (MIRM) PT Lowered to $118 at Leerink Partners
-
Mirum Pharmaceuticals (MIRM) Defended by Second Outlet, This time from Evercore: 'we think the move down is noise in a volatile tape this morning.'
-
RBC Capital Defending Mirum Pharmaceuticals (MIRM) Amid 15% Drop: 'Buying Opportunity Ahead of Multiple De-risked Catalysts'
-
Mirum Pharmaceuticals (MIRM) PT Lowered to $132 at Citizens: Has Strong Momentum
-
Mirum receives Health Canada approval for LIVMARLI tablet formulation
-
Mirum Pharmaceuticals receives Health Canada approval for LIVMARLI treatment
-
Mirum Pharmaceuticals (MIRM) PT Raised to $130 at H.C. Wainwright
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform: 'Top Pick' at Citizens
-
Mirum Pharmaceuticals (MIRM) PT Raised to $95 at Baird
-
TD Cowen on Mirum Pharmaceuticals (MIRM): 'Remain at Buy for base business and pipeline'
-
Mirum Pharmaceuticals reports preliminary 2025 sales of $520 million
-
Mirum launches phase 2 trial for Fragile X syndrome treatment
-
Mirum sues generic drugmakers over Livmarli patent infringement
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
Mirum (MIRM) PT Raised to $140 at Citizens: Outperformance Expected
-
Mirum (MIRM) PT Raised to $140 at Citizens: Outperformance Expeected
-
Mirum Pharmaceuticals (MIRM) PT Raised to $110 at Raymond James
-
Mirum Pharmaceuticals (MIRM) PT Raised to $100 at Leerink Partners
-
H.C. Wainwright Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM)
-
Leerink Partners: 'MIRM’s Bluejay Deal Nice External Recognition of HDV Value; Positive for VIR'
-
Mirum Pharmaceuticals (MIRM) PT Raised to $94 at Evercore ISI
-
Morgan Stanley: 'we view the HDV program as promising and we view the transaction as a good fit for Mirum'
-
Mirum Pharmaceuticals (MIRM) PT Raised to $88 at Baird
-
Mirum presents liver disease drug data at AASLD conference
-
Mirum Pharmaceuticals (MIRM) PT Raised to $95 at Citizens, Remains A Favorite
-
Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 20c ; Offers Guidance
-
TD Cowen Starts Mirum Pharmaceuticals (MIRM) at Buy
-
Citizens JMP Reiterates Market Outperform Rating on Mirum Pharmaceuticals (MIRM)
-
Mirum Pharmaceuticals, Inc. (MIRM) Files Mixed Shelf
-
Stifel Resumes Mirum Pharmaceuticals (MIRM) at Buy, PT $89, 'stands out in what remains a discerning biotech tape'
-
Mirum Pharmaceuticals (MIRM) PT Raised to $80 at H.C. Wainwright
-
Mirum Pharmaceuticals (MIRM) PT Raised to $81 at Citizens JMP
-
Mirum Pharmaceuticals, Inc. (MIRM) Tops Q2 EPS by 21c
-
Mirum Pharmaceuticals, Inc. (MIRM) appoints Doug Sheehy as CLO
-
H.C. Wainwright Starts Mirum Pharmaceuticals (MIRM) at Buy

